Celator Announces Trial Results For CPX-1 In Colorectal Cancer Treatment
Celator Pharmaceuticals reported positive results from its CPX-1 Phase 2 clinical trial in patients with advanced colorectal cancer. CPX-1 is a liposomal formulation of irinotecan and floxuridine, based on the company's proprietary CombiPlex technology. The results were presented in a poster presentation at the American Society of Clinical Oncology meeting in Chicago.